You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 127 No. 1, January 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement

J. M. Bohnen, J. S. Solomkin, E. P. Dellinger, H. S. Bjornson and C. P. Page
University of Toronto, Ontario Faculty of Medicine, Department of Surgery.

Several antibiotics have been marketed for therapeutic use in intra-abdominal infection. Often, these agents do not provide a sufficient spectrum activity against both facultative and obligate anaerobic gram-negative organisms, or have certain toxic effects that would not otherwise support their use. Guidelines have been developed for selection of antibiotic therapy for intra-abdominal infections and are presented as a statement of the Surgical Infection Society endorsed by the Executive Council. These guidelines are restricted to infections derived from the gastrointestinal tract and deal with those microorganisms commonly seen in such infections. The recommendations are based on in vitro activity against enteric bacteria, experience in animal models, and documented efficacy in clinical trials. Other concerns regarding pharmacokinetics, mechanisms of action, microbial resistance, and safety were also used in the formation of these guidelines. For community-acquired infections of mild to moderate severity, single-agent therapy with cefoxitin, cefotetan, or cefmetazole or ticarcillin-clavulanic acid is recommended. For more severe infections, single-agent therapy with carbapenems (imipenem/cilastatin) or combination therapy with either a third-generation cephalosporin, a monobactam (aztreonam), or an aminoglycoside plus clindamycin or metronidazole is recommended. Regimens with little or no activity against facultative gram-negative rods or anaerobic gram-negative rods are not considered acceptable.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Aminoglycoside-Based Triple-Antibiotic Therapy Versus Monotherapy for Children With Ruptured Appendicitis
Goldin et al.
Pediatrics 2007;119:905-911.
ABSTRACT | FULL TEXT  

Microdialysis Study of Imipenem Distribution in the Intraperitoneal Fluid of Rats with or without Experimental Peritonitis
Lefeuvre et al.
Antimicrob. Agents Chemother. 2006;50:34-37.
ABSTRACT | FULL TEXT  

Severe Trauma Is Not an Excuse for Prolonged Antibiotic Prophylaxis
Velmahos et al.
Arch Surg 2002;137:537-542.
ABSTRACT | FULL TEXT  

Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections
Buijk et al.
J Antimicrob Chemother 2002;49:121-128.
ABSTRACT | FULL TEXT  

It's Time to Sweat the Little Things
Weigelt
Arch Surg 2000;135:763-764.
FULL TEXT  

Bioavailability of Oral Ciprofloxacin in Early Postsurgical Patients
Hackam et al.
Arch Surg 1998;133:1221-1225.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.